Summit Therapeutics (SMMT) Reports Q3 Loss of GBP0.08/Share
Summit Therapeutics (NASDAQ: SMMT) reported Q3 EPS of (GBP0.08), versus (GBP0.06) reported last year.
For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.